Evidence map›Paper›PMID 41936857›Full record

ArticleCancer letters2026

Coordinated post-transcriptional regulation facilitates PD-L1 protein production and tumor immune suppression.

Ronghao Chen, Swetha Rajasekaran, Xuanxuan Xing, Qian Zhang, Sydney M Steele, Runjie Wang, Ananth Ponneri Babuharisankar, Jee Whu Lee, Hayden Storts, Francisco Fernandez and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ronghao ChenDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Swetha RajasekaranDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Xuanxuan XingDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Qian ZhangCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, 100049, China.
Sydney M SteeleBiophysics Program, University of Michigan, 930 N. University Ave, Ann Arbor, MI, 48109-1055, USA.
Runjie WangDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Ananth Ponneri BabuharisankarDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Jee Whu LeeDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Hayden StortsDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Francisco FernandezCenter for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA.
Miguel Guerra-SolanoCenter for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA.
Vikas KumarCenter for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA.
Sarah C KeaneBiophysics Program, University of Michigan, 930 N. University Ave, Ann Arbor, MI, 48109-1055, USA; Department of Chemistry, University of Michigan, 930 N. University Ave, Ann Arbor, MI, 48109-1055, USA.
James A WalkerCenter for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA.
Jing J WangDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA.
Wayne O MilesDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH, 43210, USA. Electronic address: wayne.miles@osumc.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Biophysics of regulatory RNAs and RNPs - Equipment SupplementR35GM138279 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sarah Courtney Keane · 2020 to 2026
$2.6M
The translation regulation of pro-apoptotic genesR01CA251753 · NCI · OHIO STATE UNIVERSITY · PI MILES, WAYNE · 2020 to 2024
$2.0M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA251753NIGMS NIH HHS R35 GM138279
6 · The paper itself

Abstract

PD-L1 drives T cell exhaustion and tumor immune evasion and is transcriptionally induced by immune cell-derived IFN-γ. Here, we find that the RNA-binding protein PUM1 recognizes a conserved 3'UTR motif in PD-L1 and is itself induced by IFN-γ. In PUM1-deficient cells, PD-L1 fails to accumulate with IFN-γ stimulation, revealing that IFN-γ also regulates PD-L1 through PUM1-mediated post-transcriptional mechanisms. Mechanistically, we identify HNRNPA2B1 as a direct competitor of PUM1 for PD-L1 mRNA binding, thereby controlling RNA stability and protein expression. In syngeneic colon cancer models, PUM1 deficiency reduces PD-L1, slows tumor growth, and enhances CD8

Indexed as

B7-H1 AntigenRNA-Binding Proteins3' Untranslated RegionsAnimalsCD8-Positive T-LymphocytesCell Line, TumorColonic NeoplasmsGene Expression Regulation, NeoplasticHeterogeneous-Nuclear Ribonucleoprotein Group A-BHumansInterferon-gammaMiceRNA, MessengerRNA Processing, Post-TranscriptionalRNA StabilityTumor Escape3' Untranslated RegionsB7-H1 AntigenCD274 protein, humanHeterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2Interferon-gammaPUM1 protein, humanRNA-Binding ProteinsRNA, MessengerHNRNPA2B1IFN-γImmune suppressionPD-L1Post-transcriptional regulationPUM1

Identifiers

PMID41936857
PMCPMC13452253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.